Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to type 2 diabetes (T2D) and obesity. However, most existing studies have examined this association in tertiary care settings. A recent study evaluated the prevalence of MASLD among 308 patients with T2D (mean age: 63.9 years) in primary care facilities. The study found that 59% of participants had MASLD, 7% had suspected advanced fibrosis, and 1.9% had cirrhosis. Patients with MASLD had a higher body mass index (31.1 vs.
27.4 kg/m²) and a greater prevalence of obesity (60% vs. 21%) compared to those without MASLD. Obesity was notably associated with an eightfold increased risk of fibrotic MASLD. Additionally, patients with MASLD showed increased levels of visceral fat, abdominal subcutaneous adipose tissue, and muscle fat infiltration. These findings suggest that T2D is more closely linked to MASLD than…
